Oric Pharmaceuticals, Inc. Common Stock (ORIC) is a publicly traded Healthcare sector company. As of May 21, 2026, ORIC trades at $8.44 with a market cap of $820.89M and a P/E ratio of -5.61. ORIC moved +5.52% today. Year to date, ORIC is +3.19%; over the trailing twelve months it is +48.32%. Its 52-week range spans $3.90 to $14.93. Analyst consensus is strong buy with an average price target of $20.89. Rallies surfaces ORIC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ORIC selects 400 mg rinzimetostat dose for Phase 3 after 93% rPFS; $420M runway: ORIC selected 400 mg once daily rinzimetostat dose for its Himalayas-1 Phase 3 trial in post-abiraterone mCRPC after data showing landmark rPFS rates of 93%, 84% and 84% at 3-5 months, with only one Grade 3 adverse event. Cash, equivalents and investments were $419.7 million, funding operations into 2H 2028.
| Metric | Value |
|---|---|
| Price | $8.44 |
| Market Cap | $820.89M |
| P/E Ratio | -5.61 |
| EPS | $-1.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.93 |
| 52-Week Low | $3.90 |
| Volume | 217 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-129.47M |
| Gross Margin | 0.00% |
11 analysts cover ORIC: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.89.